Population Trends of New Prescriptions for Antihyperglycemics and Antihypertensives Between 2014 and 2022
Authors:
- Amy Y. X. YuAYAmy Y. X. Yu
- Peter C. AustinPAPeter C. Austin
- Cynthia A. JackeviciusCJCynthia A. Jackevicius
- Anna ChuACAnna Chu
- Jessalyn K. HolodinskyJHJessalyn K. Holodinsky
- Michael D. HillMHMichael D. Hill
- Noreen KamalNKNoreen Kamal
- Mukesh KumarMKMukesh Kumar
- Douglas S. LeeDLDouglas S. Lee
- Manav V. VyasMVManav V. Vyas
- Raed A. JoundiRJRaed A. Joundi
- Nadia A. KhanNKNadia A. Khan
Open Access
- 16 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (8) , e034118
Abstract
Background: In the wake of pandemic‐related health decline and health care disruptions, there are concerns that previous gains for cardiovascular risk factors may have stalled or reversed. Population‐level excess burden of drug‐treated diabetes and hypertension during the pandemic compared with baseline is not well characterized. We evaluated the change in incident prescription claims for antihyperglycemics and antihypertensives before versus during the pandemic. Methods and Results: In this retrospective, serial, cross‐sectional, population‐based study, we used interrupted time series analyses to examine changes in the age‐ and sex‐standardized monthly rate of incident prescriptions for antihyperglycemics and antihypertensives in patients aged ≥66 years in Ontario, Canada, before the pandemic (April 2014 to March 2020) compared with during the pandemic (July 2020 to November 2022). Incident claim was defined as the first prescription filled for any medication in these classes. The characteristics of patients with incident prescriptions of antihyperglycemics (n=151 888) or antihypertensives (n=368 123) before the pandemic were comparable with their pandemic counterparts (antihyperglycemics, n=97 015; antihypertensives, n=146 524). Before the pandemic, monthly rates of incident prescriptions were decreasing (−0.03 per 10 000 individuals [95% CI, −0.04 to −0.01] for antihyperglycemics; −0.14 [95% CI, −0.18 to −0.10] for antihypertensives). After July 2020, monthly rates increased (postinterruption trend 0.31 per 10 000 individuals [95% CI, 0.28–0.34] for antihyperglycemics; 0.19 [95% CI, 0.14–0.23] for antihypertensives). Conclusions: Population‐level increases in new antihyperglycemic and antihypertensive prescriptions during the pandemic reversed prepandemic declines and were sustained for >2 years. Our findings are concerning for current and future cardiovascular health.Keywords
This publication has 39 references indexed in Scilit:
- Cost-Related Insulin Rationing in US Adults Younger Than 65 Years With DiabetesJAMA, 2023
- Diabetes and the COVID-19 pandemicDiabetologia, 2022
- Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative ReviewAdvances in Therapy, 2022
- Incidence of newly diagnosed diabetes after Covid-19Diabetologia, 2022
- Trends in Insulin Prescribing for Patients With Diabetes During the COVID-19 Pandemic in the USJAMA Network Open, 2021
- Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018JAMA, 2021
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the USJAMA Network Open, 2021
- All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25-44 Years, March-July 2020JAMA, 2021
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- County Health RankingsAmerican Journal of Preventive Medicine, 2016